Phase II study with cetuximab, irinotecan and sunitinib (CIS) for patients with treatment resistant colorectal cancer
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan (Primary) ; Sunitinib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 06 Mar 2017 New trial record